HIRA

고혈압∙당뇨병 복합질환자를 고려한 적정성 평가 개선 방안

  • 343
  • 281
Metadata Downloads
Type
Research report
Author(s)
안보령윤국회권영근
Issued Date
2022-08
Keyword
고혈압당뇨병적정성평가복합만성질환의료의 질hypertensiondiabetesquality assessment programmultimorbidity
Abstract
The Health Insurance Review and Assessment Service(HIRA) has implemented a quality assessment program since 2010 to improve the quality of medical care and reduce the risk of cardio-cerebrovascular disease by improving the management quality of patients with hypertension and diabetes.
With the increased prevalence of chronic diseases and aging populations, the modern generation generally suffers from multiple (two or more) chronic conditions simultaneously, regardless of the types of diseases. Among the patients targeted for quality assessment, 23.4% with hypertension and 59.4% with diabetes were identified as patients with multi-morbid conditions in 2019.
Thus, this study proposed measures for enhancing quality assessment program and redesigning relevant compensation systems considering muti-morbid patients with hypertension and diabetes.
Therefore, this study analyzed the current state of quality assessments program of hypertension and diabetes. It also examined international quality assessments systems, such as indicators for assessments and result analysis methods, to derive implications for assessments model design.
Moreover, it designed a quality assessment model that considers patients with hypertension and diabetes, based on implications derived from the analytical results of present conditions and international cases. Specifically, it listed preliminary indicators by reviewing existing literature, such as international quality assessment indicators, and Korean and international clinical practice guidelines. Further, it classified the listed indicators as generic and disease-specific indicators. Subsequently, it established a panel of experts and selected quality assessment indicators based on the panel’s opinions. It also examined a method that uses the selected quality assessment indicators to calculate a score based on the clinic unit and presented a grading method according to the calculated score.
Finally, this study developed a method for providing incentives based on the unit of a clinic to replace the existing method of incentivizing based on the disease. The developed method reflects the existing method that incentivizes based on the number of patients managed and sections, to consider acceptance of systems among medical institutions. However, the developed method is distinguished from the existing method in that it differentiates the level of compensation according to grades and disease types(e.g., a single disease and multiple diseases).
Additionally, this study presented a mid- and long-term direction for quality assessment indicators and compensation systems. quality assessment indicators are constantly required for implementing outcome indicators. Consequently, further research should be conducted to develop a method that reduces clinical burdens on data submission other than the claim data and to adjust the assessment results based on each medical institution by reflecting the patients’ characteristics.
The results of this study may be used as the base data for further research on quality assessment improvement.
Publisher
건강보험심사평가원
URI
https://repository.hira.or.kr/handle/2019.oak/3000
Alternative Title
Enhancement of National Quality Assessment Program Considering Multimorbidity in the Patients with Hypertension and Diabetes
Table Of Contents
제1장 서론 1
1. 연구 배경 및 목적 ·················································································· 1
2. 연구 내용 및 방법 ·················································································· 3

제2장 이론적 고찰 5
1. 복합만성질환 ·························································································· 5
가. 개념 및 정의 ····························································································· 5
나. 임상적 특성 ······························································································· 6
다. 고혈압•당뇨병 복합질환자 ·········································································· 8
2. 외국의 고혈압, 당뇨병 의료 질 평가제도 현황 ········································· 11
가. 영국 ········································································································ 11
나. 독일의 DMPs(Disease Management Programmes) ································ 21
다. 프랑스의 ROSP(Rémunération sur Objectifs de Santé Publique) ·········· 25

제3장 고혈압, 당뇨병 적정성 평가 현황 분석 33
1. 평가 대상 환자 현황 ············································································· 33
가. 고혈압, 당뇨병 환자의 질환별 의원 이용 현황 ············································· 33
나. 복합질환자 의원 이용 유형별 적정성 평가 결과 현황 ··································· 37
2. 평가 대상 기관 분석 ············································································· 38
가. 질환별 평가 대상 기관 현황 ······································································ 38
나. 고혈압 평가대상 의원의 평가결과 현황 ······················································· 42
3. 적정성 평가 결과 유형별 평가지표 현황 ················································· 50

제4장 적정성 평가 개선 방안 53
1. 평가 모형 설계 ···················································································· 53
가. 평가 대상 ································································································ 53
나. 평가 지표 ································································································ 55
다. 종합점수 산출 ·························································································· 64
라. 등급화 ····································································································· 68
2. 보상체계 재설계 ··················································································· 69
3. 중장기 방향 ························································································· 73
가. 평가 대상 ································································································ 73
나. 평가지표 개선 ·························································································· 74
다. 평가 방법 ································································································ 81
라. 지불보상 ·································································································· 82

제5장 결론 및 제언 83

◾ 참고 문헌 ······················································································· 87
◾ 부록 ······························································································· 93
◾ ABSTRACT ················································································· 103
Publisher
건강보험심사평가원
Location
KOR
Citation
안보령 et al. (202208). 고혈압∙당뇨병 복합질환자를 고려한 적정성 평가 개선 방안.
Appears in Collections:
HIRA 연구 > 1. 자체연구
Authorize & License
  • Authorize공개
Files in This Item:

열람하신 정보에 대해 만족하십니까?

Comment

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.